95- Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core
data set patient questionnaire measures distinguishes effi cacy of active treatment from that of
placebo as effectively as the American College of Rheumatology 20% response criteria
(ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis
Rheum. 2003;48(3):625–30. - Pincus T, Chung C, Segurado OG, Amara I, Koch GG. An index of patient reported outcomes
(pro-index) discriminates effectively between active and control treatment in 4 clinical trials
of adalimumab in rheumatoid arthritis. J Rheumatol. 2006;33(11):2146–52. - Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (routine assess-
ment of patient index data 3) severity categories and response criteria: similar results to
DAS28 (disease activity score) and CDAI (clinical disease activity index) in the RAPID1
(rheumatoid arthritis prevention of structural damage) clinical trial of certolizumab pegol.
Arthritis Care Res. 2011;63(8):1142–9. - Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid
arthritis. J Rheumatol. 1991;18(9):1298–306. - Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10
years after the diagnosis. J Rheumatol. 1999;26(8):1681–5. - Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheu-
matoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med.
1994;120(1):26–34. - Callahan LF, Cordray DS, Wells G, Pincus T. Formal education and fi ve-year mortality in
rheumatoid arthritis: mediation by helplessness scale score. Arthritis Care Res.
1996;9(6):463–72. - Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health
assessment questionnaire in patients with rheumatoid arthritis and the general population.
Ann Rheum Dis. 2004;63(5):494–7. - Pincus T. RAPID3, an index of only 3 patient self-report core data set measures, but not ESR,
recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid
arthritis. Bull Hosp Jt Dis. 2013;71(2):117–20. - Castrejon I, Dougados M, Combe B, Guillemin F, Fautrel B, Pincus T. Can remission in
rheumatoid arthritis be assessed without laboratory tests or a formal joint count? Possible
remission criteria based on a self-report RAPID3 score and careful joint examination in the
ESPOIR cohort. J Rheumatol. 2013;40(4):386–93. - Askanase AD, Castrejon I, Pincus T. Quantitative data for care of patients with systemic
lupus erythematosus in usual clinical settings: a patient multidimensional health assessment
questionnaire and physician estimate of noninfl ammatory symptoms. J Rheumatol.
2011;38(7):1309–16. - Castrejon I, Bergman MJ, Pincus T. MDHAQ/RAPID3 to recognize improvement over
2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondy-
loarthropathy, and gout, as well as rheumatoid arthritis. J Clin Rheumatol.
2013;19(4):169–74. - Danve A, Reddy A, Vakil-Gilani K, Garg N, Dinno A, Deodhar A. Routine assessment of
patient index data 3 score (RAPID3) correlates well with bath ankylosing spondylitis disease
activity index (BASDAI) in the assessment of disease activity and monitoring progression of
axial spondyloarthritis. Clin Rheumatol. 2015;34(1):117–24. - Cinar M, Yilmaz S, Cinar FI, Koca SS, Erdem H, Pay S, et al. A patient-reported outcome
measures-based composite index (RAPID3) for the assessment of disease activity in ankylos-
ing spondylitis. Rheumatol Int. 2015;35(9):1575–80. - Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, et al. A com-
parison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthri-
tis. PLoS One. 2015;10(4), e0123582.
3 PROMs (MDHAQ/RAPID3) and Physician RheuMetric Measures